Market Size & Trends
The North America topical drugs CDMO market size was valued at USD 2.38 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 6.79% from 2025 to 2030. Growing trends of outsourcing, increasing R&D investments due to the rising prevalence of various skin diseases, and expiration of existing patents are driving the topical drugs CDMO market in North America. Integration of advanced development and manufacturing technologies, cost-effectiveness, and a heightened number of CDMOs are some significant factors positively influencing market growth.
In addition, CDMOs have better expertise and resources pertaining to clinical trials and offer cost-effective manufacturing compared to pharmaceutical companies. Moreover, the development of innovative drugs for a specific therapeutic application is effectively managed by CDMOs, which contributes to their demand.
Growing need for novel innovation and new product development is expected to improve demand in the North America topical drugs CDMO industry, and competitive pressure & pricing concerns are driving companies to outsource new drug development & manufacturing. This is expected to drive overall market growth. In addition, an emerging focus on developing advanced drug delivery technologies for enhanced drug stability and patient outcomes is expected to propel market growth.Moreover, technological advancements enable CDMOs to cater to diverse therapeutic needs in topical drugs. This includes treatment for various skin conditions, wound care, pain management, and dermatological disorders, accelerating market growth.
The rising prevalence of skin disorders and topical ailments across North America is predicted to improve market demand. Skin conditions such as eczema, psoriasis, acne, and dermatitis have become increasingly prevalent. In addition, environmental changes, stress, dietary patterns, and genetic predispositions are some of the factors contributing to the growing patient pool, prompting a heightened need for effective topical treatments. As per the American Academy of Dermatology Association data, acne is the most common skin disorder in the U.S., accounting for over 50 million people annually. Moreover, it is estimated that around 9,500 individuals are diagnosed with skin cancer every day. Hence, the surging number of skin cancer patients in the U.S. is expected to propel the demand for novel therapeutics, accelerating the market growth. Furthermore, according to the American Burn Association, over 500 thousand individuals have burn injuries annually in the U.S. This increasing patient pool with burn injuries is also expected to improve the demand for topical drugs.
Moreover, growing consumer concern about self-care is increasing the consumption of pharmaceutical products and cosmeceuticals. The growing need for topical drugs and the rising trend for outsourcing among topical drugs promote expanding manufacturing capabilities in various locations to meet the demand. For instance, in November 2023, SOHM, Inc. introduced a new Good Manufacturing Practice (GMP) manufacturing facility in Carlsbad, California, to manufacture topical products with a capacity of 1,892 liters per day. Similarly, in April 2022, BORA Pharmaceuticals invested USD 10 million to expand its oral solid dose capabilities at its Taiwan, Zhunan, and Mississauga, Ontario facilities. The investment was planned for the next two years to meet the increasing client demand.